Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (241)	11/19/1997 1:57:00 AM
From: Miljenko Zuanic	Respond to of 328

Peter: IMO, Mikasome deserve better PR presentation from NXTR, similar to one they did in first announcement. NXTR will probably report efficiency data from other PI trials (large single dose), but this shouldn't be excuse for pure last news. Also this MiKasome PII trials for UTI has much more importance than simple target and dose indicate. If once a week dose pass it will change perception toward aminoglygosides class antibiotic. Today mainly (amikacin and gentamicin) used for systemic UTI and empiric febrile therapy (in combination with beta-lactames) will change significantly positive toward many infections indication. Serious infection (TB, pneu,onia,..) ask for weeks and months long therapy. This is MiKasome once a weeks potentials. Anyway, story is very complex. Few next Q will show how we can rate MiKasome. BTW, daily i.v. amikacin for UTI is well documented and MiKasome will be compared with amikacin data. Safety is clear, FDA scrutinity. mz

To: Biomaven who wrote (241)	12/8/1997 9:04:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 328

Peter and others: I guess the news on Abelcet, from ASH conference, contribute to recent weakness of the NXTR stock price: prnewswire.com This are not data from clinical trials, open or closed, and are selected patients from of-label usage. If someone think that this data will be base for ANDA Abelcet file for FUO indication, it is i very wrong. News indicate that part of the US Abelcet sale is from of-label usage which is well known. Also, one can speculate that AmBisome market window will be shorter and with difficulty to penetrate. To early to guess, but if EU sales comparison data are of any value, than outcome is easy to project. Anyway, did someone lately contacted NXTR IR and asked for France and expanded EU AmBisome approval (FUO and first line therapy)??? Thanks. mz